Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04587739

Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.

Hepatocellular carcinoma (HCC) is the fifth more common cancer in the world, with high mortality rates, due to the low number of patients who are eligible for therapy with curative intent, like surgical resection. Moreover, surgical resection is associated with a high risk of tumor recurrence, because of the tumor seeding through microscopic intrahepatic vessels that surround the tumor, the so-called "microvascular invasion".

To adequately deal with this phenomenon, the surgeon has to perform either an 'anatomical' liver resection, which remove not only the tumor but also the whole corresponding vascular network, or a 'tumorectomy' with resection margins of at least 2 cm. Unfortunately, these principles cannot always be achieved due to underlying liver cirrhosis that is present in more than 80% of patients.

Stereotactic body radiation therapy (SBRT) has been proven to efficiently necrotize or stabilize HCC nodules when surgery is not possible. Our hypothesis is that pre-treatment with SBRT prior to surgical resection of HCC might improve the results through the destruction of possible seeding in the peritumoral environment.

Given the novelty of this therapeutic strategy, it is necessary to verify its feasibility and safety, prior to test its efficacy in patients with HCC. The KARCHeR-1 study aims at making sure that preoperative SBRT would not result in important delays or serious adverse events such as to cancel the planned surgical resection, in patients who otherwise could have benefited from it. This issue is commonly called 'drop-out'. Thirty patients are expected to be included in the KARCHeR-1 study, which would be in favor of continuing to evaluate this therapeutic strategy if less than 3 drop-outs occur, and would be immediately discontinued if 3 drop-outs occur. Other outcomes will also been studied, like intraoperative issues, postoperative morbi-mortality, pathological features on the surgical specimen and its correlation with preoperative imaging, and finally, tumor recurrence and survival.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Hop Claude Huriez Chu Lille

Lille, 59037, France

Location status: Recruiting

Location contact

CONTACT

0320445962

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Biopsy-proven hepatocellular carcinoma or EASL/AASLD criteria
  • Single nodule, 3 to 8 cm of largest diameter
  • Hepatocellular carcinoma eligible for conventional liver resection with curative intent (R0), without preoperative portal vein embolization

Exclusion criteria

  • Performance status > 2
  • Severe comorbidity with contraindication for either surgery or radiation therapy
  • Decompensated liver cirrhosis (Child-Pugh B or C)
  • Neoplastic portal vein thrombosis or extra-hepatic metastases
  • Previous anticancer therapy within the last 5 years

Treatment and study plan

Surgery with Neoadjuvant stereotactic body radiation therapy

Combination Product

Stereotactic hypofractionated robotic radiation therapy (24-45 Gy / 3 fractions) followed after 4-6 weeks by conventional hepatectomy (either anatomical liver resection, or non-anatomical liver resection with intention to achieve a minimal 2 cm margin).

Primary outcomes

  1. Drop-out rate

    Time frame: Five months after the inclusion of the last participating patient

    Drop-out rate: proportion of patients in whom surgical resection cannot be achieved, due to (at least one of the following reasons):

    • serious adverse events related to radiation therapy (especially liver decompensation);
    • disease progression while receiving radiation therapy or awaiting surgery;
    • patient's death.

Secondary outcomes

  1. Intraoperative number of packed red blood cells transfused (if any).

    Time frame: Postoperative 90 days

  2. Toxicity of radiation therapy using the National Cancer Institute CTCAE v.5.0 criteria

    Time frame: Postoperative 90 days

  3. Duration of surgery.

    Time frame: Postoperative 90 days

  4. Volume of intraoperative blood loss

    Time frame: Postoperative 90 days

  5. Quality of life by EORTC QLQ-C30

    Time frame: between before and after stereotactic radiotherapy

  6. Intraoperative adverse events

    Time frame: Postoperative 90 days

  7. Postoperative severe and overall morbidity rate

    Time frame: Postoperative 90 days

    defined using the Comprehensive Complication Index and graded with the Dindo-Clavien score

  8. Postoperative mortality rate.

    Time frame: Postoperative 90 days

  9. Correlation between radiological observations on preoperative imaging and pathological features on surgical specimen (like percentage of tumor necrosis).

    Time frame: Postoperative day 30.

  10. Actuarial overall survival and disease-free survival.

    Time frame: Postoperative 24 months

Study contacts

Contact information is provided by the study sponsor or research team.

Emmanuel Boleslawski, MD,PhD

CONTACT

[email protected]

320444260 ext. +33

Sponsors and collaborators

Lead sponsor

University Hospital, Lille

Other

Collaborators

  • Ministry of Health, France

Registry information

Official study title

A Pilot Study on the Feasibility and Tolerance of Neoadjuvant Hypofractionated, Stereotactic Body Radiation Therapy Prior to Surgical Resection of Uninodular Hepatocellular Carcinoma.

Acronym: KARCHER-1

Important dates

Study start
2021
Primary completion
2028
Study completion
2029
First posted
Oct 14, 2020
Registry last updated
Dec 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.